These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 27335468)

  • 1. Translational and Therapeutic Approaches to the Understanding and Treatment of Dyslipidemia.
    Zhang H; de Aguiar Vallim TQ; Martel C;
    Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):e56-61. PubMed ID: 27335468
    [No Abstract]   [Full Text] [Related]  

  • 2. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
    Bajnok L
    Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside.
    Karalis I; Rensen PC; Jukema JW
    Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):360-6. PubMed ID: 23674310
    [No Abstract]   [Full Text] [Related]  

  • 4. Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters.
    Briand F; Thieblemont Q; Muzotte E; Sulpice T
    Arterioscler Thromb Vasc Biol; 2013 Jan; 33(1):13-23. PubMed ID: 23139291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9.
    van der Tuin SJ; Kühnast S; Berbée JF; Verschuren L; Pieterman EJ; Havekes LM; van der Hoorn JW; Rensen PC; Jukema JW; Princen HM; Willems van Dijk K; Wang Y
    J Lipid Res; 2015 Nov; 56(11):2085-93. PubMed ID: 26342106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Therapeutic Approaches to the Treatment of Dyslipidemia.
    Rader DJ
    Cell Metab; 2016 Mar; 23(3):405-12. PubMed ID: 26853751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.
    Yvan-Charvet L; Kling J; Pagler T; Li H; Hubbard B; Fisher T; Sparrow CP; Taggart AK; Tall AR
    Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1430-8. PubMed ID: 20448206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
    Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
    J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyslipidaemia: cardiovascular prevention--end of the road for niacin?
    Tuteja S; Rader DJ
    Nat Rev Endocrinol; 2014 Nov; 10(11):646-7. PubMed ID: 25178730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
    Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
    J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both.
    Nicholls SJ
    Clin Pharmacol Ther; 2018 Aug; 104(2):297-300. PubMed ID: 29901215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel HDL-based therapeutic agents.
    Joy TR
    Pharmacol Ther; 2012 Jul; 135(1):18-30. PubMed ID: 22465158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case report of a diabetic woman with very low HDL cholesterol.
    Chaychi L; Kinlaw WB; Asztalos BF; Schaefer EJ
    J Clin Lipidol; 2010; 4(2):133-5. PubMed ID: 21122641
    [No Abstract]   [Full Text] [Related]  

  • 14. Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.
    Chrysant SG; Ibrahim M
    J Clin Hypertens (Greenwich); 2006 Jul; 8(7):493-9; quiz 500-1. PubMed ID: 16849903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
    Costet P; Hoffmann MM; Cariou B; Guyomarc'h Delasalle B; Konrad T; Winkler K
    Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Looking into the crystal ball-upcoming drugs for dyslipidemia.
    George M; Selvarajan S; Muthukumar R; Elangovan S
    J Cardiovasc Pharmacol Ther; 2015 Jan; 20(1):11-20. PubMed ID: 25079474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H
    Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dyslipidemia and PCSK9 inhibitors - practical focused update of indication and reimbursement criteria.
    Soška V
    Vnitr Lek; 2022; 68(3):191-194. PubMed ID: 36208951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis.
    Riaz H; Khan SU; Rahman H; Shah NP; Kaluski E; Lincoff AM; Nissen SE
    Eur J Prev Cardiol; 2019 Mar; 26(5):533-543. PubMed ID: 30861690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.